BRPI0916936A8 - Composições farmacêuticas, uso de clevidipina e método de reduzir impurezas. - Google Patents
Composições farmacêuticas, uso de clevidipina e método de reduzir impurezas.Info
- Publication number
- BRPI0916936A8 BRPI0916936A8 BRPI0916936A BRPI0916936A BRPI0916936A8 BR PI0916936 A8 BRPI0916936 A8 BR PI0916936A8 BR PI0916936 A BRPI0916936 A BR PI0916936A BR PI0916936 A BRPI0916936 A BR PI0916936A BR PI0916936 A8 BRPI0916936 A8 BR PI0916936A8
- Authority
- BR
- Brazil
- Prior art keywords
- clevidipine
- pharmaceutical compositions
- reducing impurities
- active ingredient
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8559708P | 2008-08-01 | 2008-08-01 | |
US61/085,597 | 2008-08-01 | ||
US9377208P | 2008-09-03 | 2008-09-03 | |
US61/093,772 | 2008-09-03 | ||
PCT/US2009/052127 WO2010014727A1 (en) | 2008-08-01 | 2009-07-29 | Pharmaceutical compositions and methods for producing low impurity concentrations of the same |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0916936A2 BRPI0916936A2 (pt) | 2017-05-23 |
BRPI0916936A8 true BRPI0916936A8 (pt) | 2017-12-19 |
BRPI0916936B1 BRPI0916936B1 (pt) | 2020-08-04 |
BRPI0916936B8 BRPI0916936B8 (pt) | 2021-05-25 |
Family
ID=41610719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0916936A BRPI0916936B8 (pt) | 2008-08-01 | 2009-07-29 | composições farmacêuticas, uso de clevidipina e método de reduzir impurezas. |
Country Status (20)
Country | Link |
---|---|
US (5) | US20100113534A1 (pt) |
EP (2) | EP2719386A1 (pt) |
JP (1) | JP5674660B2 (pt) |
KR (1) | KR101772602B1 (pt) |
CN (1) | CN102170786B (pt) |
AU (1) | AU2009276560B2 (pt) |
BR (1) | BRPI0916936B8 (pt) |
CA (2) | CA3108961A1 (pt) |
CY (1) | CY1116490T1 (pt) |
DK (1) | DK2320740T3 (pt) |
EA (1) | EA021336B1 (pt) |
ES (1) | ES2468837T3 (pt) |
HR (1) | HRP20140434T1 (pt) |
MX (1) | MX2011001240A (pt) |
NZ (1) | NZ591205A (pt) |
PL (1) | PL2320740T3 (pt) |
PT (1) | PT2320740E (pt) |
SI (1) | SI2320740T1 (pt) |
SM (1) | SMT201400081B (pt) |
WO (1) | WO2010014727A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ591205A (en) | 2008-08-01 | 2012-11-30 | Medicines Co | Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same |
NZ610465A (en) * | 2010-10-12 | 2015-05-29 | Medicines Co | Clevidipine emulsion formulations containing antimicrobial agents |
US8658676B2 (en) | 2010-10-12 | 2014-02-25 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
CN103134891A (zh) * | 2011-11-30 | 2013-06-05 | 天津金耀集团有限公司 | 一种丁酸氯维地平含量和有关物质的测定方法 |
CN104968199A (zh) | 2012-10-26 | 2015-10-07 | 医药公司 | 用于在心力衰竭中控制血压和减轻呼吸困难的方法 |
CN103417539B (zh) * | 2013-08-22 | 2015-11-25 | 北京蓝丹医药科技有限公司 | 一种丁酸氯维地平药物组合物 |
CN104974042A (zh) * | 2014-04-09 | 2015-10-14 | 上海信谊金朱药业有限公司 | 化合物的制备方法 |
CN104974043A (zh) * | 2014-04-09 | 2015-10-14 | 上海信谊金朱药业有限公司 | 丁酸氯维地平的杂质化合物的制备方法 |
WO2015179334A1 (en) * | 2014-05-19 | 2015-11-26 | The Medicines Company | Clevidipine nanoparticles and pharmaceutical compositions thereof |
CN104458937B (zh) * | 2014-11-20 | 2017-02-22 | 北京京科泰来科技有限公司 | 一种丁酸氯维地平脂肪乳有关物质检测方法 |
CN104597192B (zh) * | 2014-12-31 | 2016-08-24 | 武汉科福新药有限责任公司 | 一种丁酸氯维地平及其制剂中有关物质的检测方法 |
CN105853353A (zh) * | 2015-01-20 | 2016-08-17 | 江苏正大丰海制药有限公司 | 一种氯维地平脂肪乳注射液的制备方法 |
CN107362139B (zh) * | 2017-08-29 | 2020-11-03 | 辅必成(上海)医药科技有限公司 | 一种丁酸氯维地平的乳剂注射液 |
WO2019123221A1 (en) * | 2017-12-20 | 2019-06-27 | Aurobindo Pharma Limited | Pharmaceutical composition comprising clevidipine and process for preparation thereof |
CN109956943B (zh) * | 2019-04-18 | 2021-07-20 | 合肥合源药业有限公司 | 一种二氢吡啶类药物中脱羧缩合杂质及其制备、控制方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4150744A (en) * | 1976-02-27 | 1979-04-24 | Smith & Nephew Pharmaceuticals Ltd. | Packaging |
DE3532129A1 (de) * | 1985-09-10 | 1987-03-12 | Bayer Ag | Ss-carotin enthaltende gelatine |
SE9303657D0 (sv) * | 1993-11-05 | 1993-11-05 | Astra Ab | Short-acting dihydropyridines |
SE9303744D0 (sv) * | 1993-11-12 | 1993-11-12 | Astra Ab | Pharmaceutical emulsion |
GB9405593D0 (en) | 1994-03-22 | 1994-05-11 | Zeneca Ltd | Pharmaceutical compositions |
SE9804002D0 (sv) * | 1998-11-23 | 1998-11-23 | Astra Ab | New manufacturing process |
US6956048B2 (en) * | 1999-03-31 | 2005-10-18 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
WO2000057885A1 (en) | 1999-03-31 | 2000-10-05 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
US6680334B2 (en) * | 2001-08-28 | 2004-01-20 | Pfizer Inc | Crystalline material |
JP2003104888A (ja) | 2001-09-28 | 2003-04-09 | Taiyo Yakuhin Kogyo Kk | ジヒドロピリジン誘導体の錠剤 |
AU2003257145B2 (en) * | 2002-08-02 | 2008-11-13 | Merck Sharp & Dohme Corp. | Substituted furo (2,3-b) pyridine derivatives |
US20060160834A1 (en) * | 2003-06-06 | 2006-07-20 | Fong Tung M | Combination therapy for the treatment of hypertension |
US20050186230A1 (en) | 2004-01-23 | 2005-08-25 | Sd Pharmaceuticals, Inc. | Elemene compositions containing liquid oil |
TW200613275A (en) * | 2004-08-24 | 2006-05-01 | Recordati Ireland Ltd | Lercanidipine salts |
CN101068546A (zh) | 2004-10-06 | 2007-11-07 | 卫材R&D管理有限公司 | 医药组合物及其制造方法以及医药组合物中的二氢吡啶类化合物的稳定化方法 |
US20100016378A1 (en) * | 2005-04-28 | 2010-01-21 | Toshio Suzuki | Method of preventing dihydropyridine compound from degradation |
US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
CA2616806A1 (en) * | 2005-07-28 | 2007-02-08 | Reliant Pharmaceuticals, Inc. | Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof |
NZ591205A (en) | 2008-08-01 | 2012-11-30 | Medicines Co | Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same |
WO2010022259A1 (en) | 2008-08-22 | 2010-02-25 | Milestone Pharmaceuticals Inc. | Short acting benzothiazepine calcium channel blockers and uses thereof |
CN101766568A (zh) | 2008-12-31 | 2010-07-07 | 北京利乐生制药科技有限公司 | 一种含有氯维地平的乳剂及其制备工艺和用途 |
CN101780036B (zh) | 2010-03-30 | 2011-11-16 | 武汉武药科技有限公司 | 丁酸氯维地平脂微球注射液及其制备方法 |
NZ610465A (en) | 2010-10-12 | 2015-05-29 | Medicines Co | Clevidipine emulsion formulations containing antimicrobial agents |
US8658676B2 (en) | 2010-10-12 | 2014-02-25 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
-
2009
- 2009-07-29 NZ NZ591205A patent/NZ591205A/xx unknown
- 2009-07-29 CA CA3108961A patent/CA3108961A1/en active Pending
- 2009-07-29 EP EP14150954.7A patent/EP2719386A1/en not_active Withdrawn
- 2009-07-29 WO PCT/US2009/052127 patent/WO2010014727A1/en active Application Filing
- 2009-07-29 AU AU2009276560A patent/AU2009276560B2/en active Active
- 2009-07-29 DK DK09803550.4T patent/DK2320740T3/da active
- 2009-07-29 SI SI200930923T patent/SI2320740T1/sl unknown
- 2009-07-29 JP JP2011521291A patent/JP5674660B2/ja active Active
- 2009-07-29 US US12/511,631 patent/US20100113534A1/en not_active Abandoned
- 2009-07-29 CN CN200980139203.6A patent/CN102170786B/zh active Active
- 2009-07-29 KR KR1020117004358A patent/KR101772602B1/ko active IP Right Grant
- 2009-07-29 ES ES09803550.4T patent/ES2468837T3/es active Active
- 2009-07-29 BR BRPI0916936A patent/BRPI0916936B8/pt active IP Right Grant
- 2009-07-29 CA CA2732760A patent/CA2732760A1/en not_active Abandoned
- 2009-07-29 PT PT98035504T patent/PT2320740E/pt unknown
- 2009-07-29 MX MX2011001240A patent/MX2011001240A/es active IP Right Grant
- 2009-07-29 EP EP09803550.4A patent/EP2320740B1/en active Active
- 2009-07-29 EA EA201170289A patent/EA021336B1/ru not_active IP Right Cessation
- 2009-07-29 PL PL09803550T patent/PL2320740T3/pl unknown
-
2012
- 2012-08-30 US US13/600,056 patent/US20120322835A1/en not_active Abandoned
-
2013
- 2013-06-17 US US13/919,893 patent/US20140005233A1/en not_active Abandoned
-
2014
- 2014-05-13 HR HRP20140434AT patent/HRP20140434T1/hr unknown
- 2014-05-30 CY CY20141100388T patent/CY1116490T1/el unknown
- 2014-06-25 SM SM201400081T patent/SMT201400081B/xx unknown
-
2018
- 2018-11-21 US US16/197,647 patent/US11058672B2/en active Active
-
2021
- 2021-06-16 US US17/304,216 patent/US20220000849A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0916936A8 (pt) | Composições farmacêuticas, uso de clevidipina e método de reduzir impurezas. | |
BRPI1103213B8 (pt) | Composição de enxaguatório bucal antimicrobiano com teor alcoólico reduzido à base de óleo essencial bioativo | |
BR112018008684A2 (pt) | formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético | |
BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
EA201291108A1 (ru) | Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген | |
BRPI0617294B8 (pt) | composição farmacêutica em gel hidroalcóolico e uso de testosterona | |
CU20060153A7 (es) | Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen | |
BR112012010083B8 (pt) | Composição farmacêutica tópica de liberação sustentada e uso relacionado | |
UY31080A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis | |
ECSP11011278A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
MX2011002065A (es) | Composicion farmaceutica a base de progesterona micronizada y sus usos. | |
AR054581A1 (es) | Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion | |
CR20110596A (es) | Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas | |
DOP2012000324A (es) | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4metil-piperazin-1il)-1h-bencimidazol-2-il)-1h-quinolin-2-ona | |
BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
BR112012009487A2 (pt) | formulações de espessante estáveis | |
BR112012012862A2 (pt) | composição farmacêutica compreendendo oligopeptídeos | |
BR112012032882A2 (pt) | liberação aumentada de ingredientes lopofílicos de goma de mascar com hidrocoloides | |
NI201900063A (es) | Amidas aromáticas de ácido carboxílico | |
BRPI0608395A2 (pt) | composição farmacêutica sólida que compreende telitromicina | |
BRPI0416747A (pt) | métodos e formulações para o tratamento de condições médicas relacionadas à dihidrotesterona elevada | |
BRPI0602179A (pt) | composição farmacêutica compreendendo ciclobenzaprina e aceclofenaco em combinação | |
BR112013000296A2 (pt) | agentes terapêuticos 976 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25A | Requested transfer of rights approved |
Owner name: HOSPIRA, INC (US) , CHIESI FARMACEUTICI S.P.A. (IT |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |